Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ACCORD blood pressure, 2010 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ACCOMPLISH (diabetic subgroup), 2010 - benazepril + amlodipine vs benazepril + hydrochlorothiazide

AVOID, 2008 - aliskiren vs placebo

ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002 - amlodipine vs chlorthalidone

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril vs chlorthalidone

LIFE (diabetic subgroup), 2002 - losartan vs atenolol

IDNT (irbesartan vs amlodipine), 2001 - Irbesartan vs amlodipine

IPDM, 2001 - irbesartan vs placebo

IDNT amlodipine, 2001 - amlodipine vs placebo

RENAAL, 2001 - losartan vs placebo

IDNT irbesartan, 2001 - Irbesartan vs placebo

NORDIL (diabetic subgroup), 2000 - Diltiazem vs diuretic or beta-blocker

STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor vs CCB

HOPE (diabetic subgroup), 2000 - ACE inhibitor vs placebo

STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor vs diuretic or beta-blocker

STOP-2 CCB (diabetic subgroup), 2000 - calcium-channel blocker vs diuretic or beta-blocker

INSIGHT (diabetic subgroup), 2000 - Nifedipine vs coamilozide

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

CAPP (diabetic subgroup), 1999 - captopril vs diuretic or beta-blocker

Syst-Eur (diabetic subgroup), 1999 - nitrendipine vs placebo

UKPDS 38, 1998 - captopril or atenolol vs control

UKPDS 39, 1998 - captopril vs atenolol

ABCD, 1998 - nisoldipine vs enalapril

FACET, 1997 - amlodipine vs fosinopril



See also:

  • All diabetes clinical trials
  • All hypertension clinical trials
  • All clinical trials of anti hypertensive agent
  • All clinical trials of amlodipine
  •  

    FACET study, 1997

    Treatments

    Studied treatment amlodipine (long acting) 10 mg daily
    Control treatment fosinopril 20 mg daily
    Remarks if blood pressure was not controlled, the other study drug was added

    Patients

    Patients hypertensive patients with NIDDM
    Inclusion criteria diagnosis of NIDDM and hypertension (systolic blood pre ssure of 140 mmHg or diastolic blood pressure of 90 mmHg)
    Exclusion criteria history of coronary heart disease or stroke, serum creatinine >1.5 mg/dl, albuminuria >40 ìg/min, and use of lipid-lowering drugs, aspirin, or antihypertensive agents other than beta-blockers or diuretics
    Baseline characteristics
    Glycosylated hemoglobin 7.0 %  
    BP (systolic/diastolic) 170/95 
    Female (%) 40% 
    Age 63 y 
    subgroup no 
    hypertension (%) 100% 

    Method and design

    Randomized effectives 191 / 189 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 3.5 y
    Lost to follow-up ND
    Number of centre single center
    Geographic area Italy
    Hypothesis Superiority
    Primary endpoint not defined
    Withdrawals (T1/T0) ND /


    Results



    Endpoints and data reported in the trial's publication(s)

    Endpoint Events (%) Relative Risk 95% CI
    Studied treat. Control treat.
    All-cause mortality 5 / 191 (2,6%) 4 / 189 (2,1%) 1,24 [0,34;4,54]
    Fatal or nonfatal stroke 10 / 191 (5,2%) 4 / 189 (2,1%) 2,47 [0,79;7,75]
    Fatal or nonfatal acute myocardial infarction 13 / 191 (6,8%) 10 / 189 (5,3%) 1,29 [0,58;2,86]
    Hospitalized angina 4 / 191 (2,1%) 0 / 189 (0,3%) 7,92 [0,42;148,71]
    Any major vascular event 27 / 191 (14,1%) 14 / 189 (7,4%) 1,91 [1,03;3,52]
    Coronary artery bypass 2 / 191 (1,0%) 3 / 189 (1,6%) 0,66 [0,11;3,90]
    Percutaneous transluminal coronary angioplasty 1 / 191 (0,5%) 0 / 189 (0,3%) 1,98 [0,07;58,64]
    Any major vascular event or procedure 27 / 191 (14,1%) 14 / 189 (7,4%) 1,91 [1,03;3,52]
    Other cardiovascular events or procedures 5 / 191 (2,6%) 4 / 189 (2,1%) 1,24 [0,34;4,54]
    Any death or any vascular event or any procedure 34 / 191 (17,8%) 20 / 189 (10,6%) 1,68 [1,01;2,81]
    Nonfatal cancer 9 / 191 (4,7%) 7 / 189 (3,7%) 1,27 [0,48;3,35]
    Fatal cancer 2 / 191 (1,0%) 1 / 189 (0,5%) 1,98 [0,18;21,64]
    Any cancer 11 / 191 (5,8%) 8 / 189 (4,2%) 1,36 [0,56;3,31]
    Any event listed above 42 / 191 (22,0%) 27 / 189 (14,3%) 1,54 [0,99;2,39]

    Endpoints used by the meta-analysis and data retained for this trial

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    cardiovascular event (fatal and non fatal)

    27 / 191
    14 / 189
    classic 1,91 [1,03;3,52]

    Cardiovascular death

    10 / 235
    5 / 235
    classic 2,00 [0,69;5,76]

    All cause death

    5 / 191
    4 / 189
    classic 1,24 [0,34;4,54]

    stroke (fatal and non fatal)

    10 / 191
    4 / 189
    classic 2,47 [0,79;7,75]

    myocardial infarction (fatal and non fatal)

    13 / 191
    10 / 189
    classic 1,29 [0,58;2,86]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    cardiovascular event (fatal and non fatal) 27 / 191 (14,1%) 14 / 189 (7,4%) 1,91 [1,03;3,52] Any major vascular event   
    Cardiovascular death 10 / 235 (4,3%) 5 / 235 (2,1%) 2,00 [0,69;5,76]    
    All cause death 5 / 191 (2,6%) 4 / 189 (2,1%) 1,24 [0,34;4,54] All-cause mortality   
    stroke (fatal and non fatal) 10 / 191 (5,2%) 4 / 189 (2,1%) 2,47 [0,79;7,75] Fatal or nonfatal stroke  12506 
    myocardial infarction (fatal and non fatal) 13 / 191 (6,8%) 10 / 189 (5,3%) 1,29 [0,58;2,86] Fatal or nonfatal acute myocardial infarction  12506 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12506: Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo FOutcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.Diabetes Care 1998 Apr;21:597-603

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    cardiovascular event (fatal and non fatal) 14,14% 7,41% 6,7%
    Cardiovascular death 4,26% 2,13% 2,1%
    All cause death 2,62% 2,12% 5,0‰
    stroke (fatal and non fatal) 5,24% 2,12% 3,1%
    myocardial infarction (fatal and non fatal) 6,81% 5,29% 1,5%


    Reference(s)

    Trials register # NA
    • Tatti et al. . . Circulation 1997; 96:I-764 (abstr)
      Pubmed | Hubmed | Fulltext
    • Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.. Diabetes Care 1998 Apr;21:597-603
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend